News | March 01, 2025
Biocon launches GLP -1, Liraglutide, in UK
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Cancer cases in India estimated to reach 1.57 million in 2025
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
These solutions combine scientifically or clinically validated, regulatory-approved probiotic strains with precise dosing
Subscribe To Our Newsletter & Stay Updated
